A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/00 (2006.01) A61K 31/5377 (2006.01) A61K 47/00 (2006.01) A61K 47/02 (2006.01) A61K 47/14 (2006.01) A61K 47/20 (2006.01)
Patent
CA 2758534
An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
L'invention porte sur une composition pharmaceutique administrable par voie orale qui comprend un système support de médicament ayant un composé inhibiteur de protéine de la famille Bcl-2, par exemple ABT-263, en solution dans un support sensiblement non aqueux qui comprend au moins un phospholipide et un agent solubilisant pharmaceutiquement acceptable. La composition est appropriée pour l'administration orale à un sujet en ayant besoin pour le traitement d'une maladie caractérisée par la surexpression d'une ou plusieurs protéines anti-apoptotiques de la famille Bcl-2, par exemple le cancer.
David Paul
Fickes Michael
Fischer Cristina
Haight Anthony R.
Heemstra Katherine
Abbott Laboratories
Torys Llp
LandOfFree
Lipid formulation of apoptosis promoter does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipid formulation of apoptosis promoter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid formulation of apoptosis promoter will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1737693